Chromatographic purification and properties of a therapeutic human protein C concentrate

M. Radosevich, F. L. Zhou, J. J. Huart, T. Burnouf

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Protein C deficiency (inherited and acquired) has a relatively high incidence rate in the general population worldwide. For many years, protein C deficient patients have been treated with fresh frozen plasma, prothrombin complex concentrates, heparin or oral anticoagulants, which all have clinical drawbacks. We report the production process of a highly purified human protein C concentrate from 1500 l of cryo-poor plasma by a four-step chromatographic procedure. After DEAE-Sephadex adsorption, protein C was separated from clotting factors II, VII and IX by DEAE-Sepharose FF and further purified, using a new strategy, by an on-line chromatographic system combining DMAE-Fractogel and heparin-Sepharose CL-6B. In addition, the product was treated against viral risks by solvent-detergent and nanofiltration on 15-nm membranes. The protein C concentrate was essentially free of other vitamin K-dependent proteins. Proteolytic activity was undetectable. Neither activated protein C, prekallikrein activator, nor activated vitamin K-dependent clotting factors were found resulting in good stability of the protein C activity. In vitro and in vivo animal tests did not reveal any sign of potential thrombogenicity. The final freeze-dried product had a mean protein C concentration of 58 IU/ml and a mean specific activity of 215 IU/mg protein, corresponding to over 12 000-fold purification from plasma. Therefore, this concentrate appears to be of potential benefit for the treatment of protein C deficiency.

Original languageEnglish
Pages (from-to)199-207
Number of pages9
JournalJournal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
Volume790
Issue number1-2
DOIs
Publication statusPublished - Jun 25 2003
Externally publishedYes

Fingerprint

Protein C
Purification
Blood Coagulation Factors
Vitamin K
Therapeutics
Plasmas
Factor XIIa
Protein C Deficiency
Online Systems
DEAE-Dextran
Factor VII
Factor IX
Prothrombin
Nanofiltration
Detergents
Sepharose
Anticoagulants
Adsorption
Heparin
Proteins

Keywords

  • Factor II
  • Factor IX
  • Factor VII
  • Protein C
  • Proteins

ASJC Scopus subject areas

  • Biochemistry

Cite this

Chromatographic purification and properties of a therapeutic human protein C concentrate. / Radosevich, M.; Zhou, F. L.; Huart, J. J.; Burnouf, T.

In: Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 790, No. 1-2, 25.06.2003, p. 199-207.

Research output: Contribution to journalArticle

@article{0d8c74f74ef64dcdafbc5ee9deeb8684,
title = "Chromatographic purification and properties of a therapeutic human protein C concentrate",
abstract = "Protein C deficiency (inherited and acquired) has a relatively high incidence rate in the general population worldwide. For many years, protein C deficient patients have been treated with fresh frozen plasma, prothrombin complex concentrates, heparin or oral anticoagulants, which all have clinical drawbacks. We report the production process of a highly purified human protein C concentrate from 1500 l of cryo-poor plasma by a four-step chromatographic procedure. After DEAE-Sephadex adsorption, protein C was separated from clotting factors II, VII and IX by DEAE-Sepharose FF and further purified, using a new strategy, by an on-line chromatographic system combining DMAE-Fractogel and heparin-Sepharose CL-6B. In addition, the product was treated against viral risks by solvent-detergent and nanofiltration on 15-nm membranes. The protein C concentrate was essentially free of other vitamin K-dependent proteins. Proteolytic activity was undetectable. Neither activated protein C, prekallikrein activator, nor activated vitamin K-dependent clotting factors were found resulting in good stability of the protein C activity. In vitro and in vivo animal tests did not reveal any sign of potential thrombogenicity. The final freeze-dried product had a mean protein C concentration of 58 IU/ml and a mean specific activity of 215 IU/mg protein, corresponding to over 12 000-fold purification from plasma. Therefore, this concentrate appears to be of potential benefit for the treatment of protein C deficiency.",
keywords = "Factor II, Factor IX, Factor VII, Protein C, Proteins",
author = "M. Radosevich and Zhou, {F. L.} and Huart, {J. J.} and T. Burnouf",
year = "2003",
month = "6",
day = "25",
doi = "10.1016/S1570-0232(03)00091-6",
language = "English",
volume = "790",
pages = "199--207",
journal = "Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences",
issn = "1570-0232",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Chromatographic purification and properties of a therapeutic human protein C concentrate

AU - Radosevich, M.

AU - Zhou, F. L.

AU - Huart, J. J.

AU - Burnouf, T.

PY - 2003/6/25

Y1 - 2003/6/25

N2 - Protein C deficiency (inherited and acquired) has a relatively high incidence rate in the general population worldwide. For many years, protein C deficient patients have been treated with fresh frozen plasma, prothrombin complex concentrates, heparin or oral anticoagulants, which all have clinical drawbacks. We report the production process of a highly purified human protein C concentrate from 1500 l of cryo-poor plasma by a four-step chromatographic procedure. After DEAE-Sephadex adsorption, protein C was separated from clotting factors II, VII and IX by DEAE-Sepharose FF and further purified, using a new strategy, by an on-line chromatographic system combining DMAE-Fractogel and heparin-Sepharose CL-6B. In addition, the product was treated against viral risks by solvent-detergent and nanofiltration on 15-nm membranes. The protein C concentrate was essentially free of other vitamin K-dependent proteins. Proteolytic activity was undetectable. Neither activated protein C, prekallikrein activator, nor activated vitamin K-dependent clotting factors were found resulting in good stability of the protein C activity. In vitro and in vivo animal tests did not reveal any sign of potential thrombogenicity. The final freeze-dried product had a mean protein C concentration of 58 IU/ml and a mean specific activity of 215 IU/mg protein, corresponding to over 12 000-fold purification from plasma. Therefore, this concentrate appears to be of potential benefit for the treatment of protein C deficiency.

AB - Protein C deficiency (inherited and acquired) has a relatively high incidence rate in the general population worldwide. For many years, protein C deficient patients have been treated with fresh frozen plasma, prothrombin complex concentrates, heparin or oral anticoagulants, which all have clinical drawbacks. We report the production process of a highly purified human protein C concentrate from 1500 l of cryo-poor plasma by a four-step chromatographic procedure. After DEAE-Sephadex adsorption, protein C was separated from clotting factors II, VII and IX by DEAE-Sepharose FF and further purified, using a new strategy, by an on-line chromatographic system combining DMAE-Fractogel and heparin-Sepharose CL-6B. In addition, the product was treated against viral risks by solvent-detergent and nanofiltration on 15-nm membranes. The protein C concentrate was essentially free of other vitamin K-dependent proteins. Proteolytic activity was undetectable. Neither activated protein C, prekallikrein activator, nor activated vitamin K-dependent clotting factors were found resulting in good stability of the protein C activity. In vitro and in vivo animal tests did not reveal any sign of potential thrombogenicity. The final freeze-dried product had a mean protein C concentration of 58 IU/ml and a mean specific activity of 215 IU/mg protein, corresponding to over 12 000-fold purification from plasma. Therefore, this concentrate appears to be of potential benefit for the treatment of protein C deficiency.

KW - Factor II

KW - Factor IX

KW - Factor VII

KW - Protein C

KW - Proteins

UR - http://www.scopus.com/inward/record.url?scp=0038062925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038062925&partnerID=8YFLogxK

U2 - 10.1016/S1570-0232(03)00091-6

DO - 10.1016/S1570-0232(03)00091-6

M3 - Article

C2 - 12767332

AN - SCOPUS:0038062925

VL - 790

SP - 199

EP - 207

JO - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

JF - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

SN - 1570-0232

IS - 1-2

ER -